Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Lenalidomide has been linked to myelodysplastic syndrome (MDS) after autotransplants for myeloma. Total therapy trials (TT; TT2(−/+) thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Usmani, Saad Z., Sawyer, Jeffrey, Rosenthal, Adam, Cottler-Fox, Michele, Epstein, Joshua, Yaccoby, Shmuel, Sexton, Rachael, Hoering, Antje, Singh, Zeba, Heuck, Christoph J., Waheed, Sarah, Chauhan, Nabeel, Johann, Donald, Abdallah, Al-Ola, Muzaffar, Jameel, Petty, Nathan, Bailey, Clyde, Crowley, John, van Rhee, Frits, Barlogie, Bart
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2013
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674673/
https://ncbi.nlm.nih.gov/pubmed/23603914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-11-466961
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak